Insmed Appoints Dr. Eugene Sullivan as Chief Medical and Scientific Officer
23 Mars 2015 - 2:00PM
Business Wire
20 Year Industry Veteran Brings Industry,
Clinical and Regulatory Experience in Pulmonary and Orphan
Diseases
Insmed Incorporated (NASDAQ:INSM) today announced that Eugene
Sullivan, M.D. has joined Insmed as its Chief Medical and
Scientific Officer. Dr. Sullivan will report to Will Lewis,
President and Chief Executive Officer. Several highlights from Dr.
Sullivan’s career include:
- Former pulmonary physician at the
Cleveland Clinic
- Former Deputy Director at US Food and
Drug Administration
- Former Chief Medical Officer of United
Therapeutics
Dr. Sullivan joins Insmed with more than 20 years of experience
with a focus on pulmonary and orphan diseases. He is a medical
doctor trained in internal medicine, pulmonary medicine and
critical care medicine and practiced at the Cleveland Clinic from
1995 to 1999. From 1999 through 2006, Dr. Sullivan held several
positions at the U.S. Food and Drug Administration, including
Deputy Director of the Division of Pulmonary and Allergy Products.
From 2007 through 2012, Dr. Sullivan was the Chief Medical Officer
of United Therapeutics. In recent years, Dr. Sullivan was a Vice
President, Global Regulatory Affairs at Astra Zeneca and consulted
to companies, including Insmed, on clinical drug development and
strategic regulatory matters.
"I am extremely pleased to welcome Gene to the Insmed team. His
broad clinical and regulatory experience with both development
stage and commercial products will be very valuable to Insmed. Gene
is actively involved as an author, lecturer and advisor on medical
and regulatory matters affecting orphan drugs and pulmonary
diseases. His experience will provide new insight and valuable
perspective as we advance ARIKAYCE, INS1009 and our other pipeline
candidates while building Insmed into a leading biopharmaceutical
company,” said Mr. Lewis.
“It is a pleasure to join Will and the Insmed team. The
Company’s focus on developing and acquiring therapeutics for unmet
medical needs in pulmonary and orphan diseases offers a very
exciting professional opportunity. Throughout my career I have been
keenly focused on delivering benefit to patients in these
underserved therapeutic indications. I look forward to being a part
of this dynamic leadership team as we bring new treatments to
patients suffering from these serious lung diseases,” commented Dr.
Sullivan.
Dr. Sullivan graduated summa cum laude from the University of
Maryland with a Bachelor of Science degree. He earned his medical
degree from the University of Maryland, School of Medicine and
conducted his internship and residency in Internal Medicine at the
Medical College of Virginia. Dr. Sullivan completed his fellowship
training in Pulmonary and Critical Care Medicine at the University
of Colorado Health Sciences Center and received a Masters of
Pulmonary Vascular Disease from the University of Bologna in
Italy.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKAYCE™, or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: patients with nontuberculous
mycobacteria (NTM) lung infections and cystic fibrosis (CF)
patients with Pseudomonas aeruginosa lung infections. Insmed is
also focused on the development of INS1009, the Company’s inhaled
treprostinil prodrug for the treatment of pulmonary arterial
hypertension (PAH), a chronic, life-threatening disorder
characterized by abnormally high blood pressure in the arteries
between the heart and lungs. For more information, please visit
http://www.insmed.com.
Forward-looking statements
This release contains forward-looking statements. Words, and
variations of words, such as “intend,” “expect,” “will,”
“anticipate,” “believe,” “continue,” “propose” and similar
expressions are intended to identify forward-looking statements.
Investors are cautioned that such statements in this release,
including statements relating to the status, results and timing of
clinical trials and clinical data, the anticipated benefits of
Insmed’s products, the anticipated timing of regulatory
submissions, and the ability to obtain required regulatory
approvals, bring products to market and successfully commercialize
products constitute forward-looking statements that involve risks
and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. Such risks
and uncertainties include, without limitation, failure or delay of
European, Canadian, U.S. Food and Drug Administration and other
regulatory reviews and approvals, competitive developments
affecting the Company’s product candidates, delays in product
development or clinical trials or other studies, patent disputes
and other intellectual property developments relating to the
Company’s product candidates, unexpected regulatory actions, delays
or requests, the failure of clinical trials or other studies or
results of clinical trials or other studies that do not meet
expectations, the fact that subsequent analyses of clinical trial
or study data may lead to different (including less favorable)
interpretations of trial or study results or may identify important
implications of a trial or study that are not reflected in
Company’s prior disclosures, and the fact that trial or study
results or subsequent analyses may be subject to differing
interpretations by regulatory agencies, the inability to
successfully develop the Company’s product candidates or receive
necessary regulatory approvals, the inability to make product
candidates commercially successful, changes in anticipated
expenses, changes in the Company’s financing requirements or
ability to raise additional capital, and other risks and challenges
detailed in the Company’s filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K
for the year ended December 31, 2014. Investors are cautioned
not to place undue reliance on any forward-looking statements that
speak only as of the date of this news release. The Company
undertakes no obligation to update these forward-looking statements
to reflect events or circumstances or changes in its
expectations.
Investor Relations:LHAAnne Marie Fields,
212-838-3777Senior Vice Presidentafields@lhai.comorBruce Voss,
310-691-7100Managing Directorbvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024